(Q37235598)

English

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

scientific article published on 18 April 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia (English)

1 reference

Europe PubMed Central

19 August 2017

phase II clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

fallopian tube cancer

1 reference

based on heuristic

inferred from title

fallopian tube carcinoma

1 reference

based on heuristic

inferred from title

Everett E Vokes

9

object named as

Everett E Vokes

1 reference

Europe PubMed Central

19 August 2017

7

object named as

Ravi Salgia

1 reference

Europe PubMed Central

19 August 2017

author name string

Halla S Nimeiri

1

1 reference

Europe PubMed Central

19 August 2017

Amit M Oza

2

1 reference

Europe PubMed Central

19 August 2017

Robert J Morgan

3

1 reference

Europe PubMed Central

19 August 2017

Gregory Friberg

4

1 reference

Europe PubMed Central

19 August 2017

Kristen Kasza

5

1 reference

Europe PubMed Central

19 August 2017

Leonardo Faoro

6

1 reference

Europe PubMed Central

19 August 2017

Walter M Stadler

8

1 reference

Europe PubMed Central

19 August 2017

Gini F Fleming

10

1 reference

Europe PubMed Central

19 August 2017

Chicago Phase II Consortium

11

1 reference

Europe PubMed Central

19 August 2017

PMH Phase II Consortium

12

1 reference

Europe PubMed Central

19 August 2017

California Phase II Consortium

13

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

18 April 2008

1 reference

Europe PubMed Central

19 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

19 August 2017

110

1 reference

Europe PubMed Central

19 August 2017

1

1 reference

Europe PubMed Central

19 August 2017

49-55

1 reference

Europe PubMed Central

19 August 2017

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

Gastrointestinal perforation due to bevacizumab in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

The prognostic significance of angiogenesis in epithelial ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

9 September 2017

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

14 September 2017

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Vascular endothelial growth factor serum concentrations in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

3 September 2018

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699608

4 December 2018

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

The role of bevacizumab in ovarian cancer--an evolving story

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.009

7 January 2021

Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/18423560

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18423560

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18423560

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18423560

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2008.02.009

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37235598&oldid=2105462003"